FDG-PET/MRI imaging for the evaluation of early response to nivolumab in patients with previously treated non-small cell lung cancer

Not Applicable

• Conditions: Previously treated non-small cell lung cancer

• Registration Number: JPRN-UMIN000020707
• Lead Sponsor: Third department of internal medicine, Universtiy of Fukui

Brief Summary

Patients with non-progressive disease (non-PD) had significantly decreased TLG, increased ADCmean (that is, negative dADCmean), and lower dTLG+dADCmean than patients with PD. Among the parameters tested, receiver operating characteristic curve analysis revealed that a cut-off value of 16.5 for dTLG+dADCmean had the highest accuracy (92%) for distinguishing between non-PD and PD patients.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-01-23
• Study Completion: 2018-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

Not provided

Exclusion Criteria

1) Fasting serum glucose levels above 150 mg/dl 2) Pregnant woman 3) Patients with metalic device in their body 4) Patients with claustrophobia 5) Patients with obvious interstitial pneumonia or pulmonary fibrosis in the chest X-ray. 6) Patients with collagen vascular disease or autoimmune diseases 7) Other cases attending physician it is determined unsuitable for registration of the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Relationship between serial FDG-PET/MRI findings and progression free survival and tumor response.

Secondary Outcome Measures

Name	Time	Method
1. Association of serial change of FDG-PET/MRI findings with overall survival. 2. To evaluate the FDG-PET/MRI findings of side effect of nivolumab therapy. 3. Association of FDG-PET/MRI findings and PD-L1 expression of lung cancer.